SAVARA, INC.
hotel management and consulting services for boutique and lifestyle hotels
- Sector
- Biotech
- Headquarters
- AUSTIN, TX
- Latest Form D
- $26.8M, Jan 2020
- Total capital
- $32M
- Federal grants
- $1M
- 1 award · 2015
- Rank in peer group#296 of 326
- Private capital raised
- $30.9M
- 2 Form D · last Jan 2020
- 82 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 9 pending · first 2017
- Rank in peer group#35 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$26.8M
- Federal grantHealth and Human S · Phase II · Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1M
- Private capital raisedForm D · SEC · 1st filing$4.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#35 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- John S. LordResearcherExecutive OfficerLinked by 3 patents
- Taneli JouhikainenResearcherExecutive OfficerLinked by $1M in grants as PI
- An J. van Es-JohanssonDirectorNamed in SEC Form D filings
- Badrul J. ChowdhuryExecutive OfficerNamed in SEC Form D filings
- Chris MarichExecutive OfficerNamed in SEC Form D filings
- Cory BerklandExecutive OfficerNamed in SEC Form D filings
Show all 25 people
- Curt BilbyDirectorNamed in SEC Form D filings
- David L. LowranceExecutive OfficerNamed in SEC Form D filings
- David A. RamsayDirectorNamed in SEC Form D filings
- George LaurenceExecutive Officer, DirectorNamed in SEC Form D filings
- Joe McCrackenDirectorNamed in SEC Form D filings
- Joseph S. McCrackenDirectorNamed in SEC Form D filings
- Kate J. McCabeExecutive OfficerNamed in SEC Form D filings
- Matthew DennisDirectorNamed in SEC Form D filings
- Matthew A. PaulsDirectorNamed in SEC Form D filings
- Mike J. CieslaExecutive OfficerNamed in SEC Form D filings
- Nevan ElamDirectorNamed in SEC Form D filings
- Peter J. GinsburgExecutive OfficerNamed in SEC Form D filings
- Richard BenkendorfDirectorNamed in SEC Form D filings
- Richard J. HawkinsDirectorNamed in SEC Form D filings
- Rick HawkinsDirectorNamed in SEC Form D filings
- Ricky J. SunDirectorNamed in SEC Form D filings
- Robert NevilleExecutive Officer, DirectorNamed in SEC Form D filings
- Shirley GeeDirectorNamed in SEC Form D filings
- Yuri PikoverDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 13- PendingDrug-device CombinationUSPTOApplication 18848745
- PendingMethods For The Treatment Of Autoimmune Pulmonary Alveolar ProteinosisUSPTOApplication 18247431
- PendingDry Powder Vancomycin Compositions And Associated MethodsUSPTOApplication 17140755
Show all 13 patent records
- Drug-device CombinationFeb 19, 2026 · Application 18848745Pending
- Methods For The Treatment Of Autoimmune Pulmonary Alveolar ProteinosisFeb 27, 2025 · Application 18247431Pending
- Dry Powder Vancomycin Compositions And Associated MethodsMay 27, 2021 · Application 17140755Pending
- Dry Powder Vancomycin Compositions And Associated MethodsMay 21, 2020 · Application 16737231Pending
- Separation of Vancomycin and its Degradation ProductsApr 16, 2020 · Application 16653740Pending
- Dry Powder Vancomycin Compositions And Associated MethodsFeb 18, 2020 · US 10,561,608Granted
- Dry Powder Vancomycin Compositions And Associated MethodsSep 24, 2019 · US 10,420,722Granted
- Formulations Of Aminoglycosides And Fosfomycin In A Combination Having Improved Chemical PropertiesSep 10, 2019 · US 10,406,171Granted
- Dry Powder Vancomycin Compositions And Associated MethodsFeb 21, 2017 · US 9,572,774Granted
- Dry Powder Vancomycin Compositions And Associated MethodsApplication PCTUS2012038775Pending
- Methods For The Treatment Of Autoimmune Pulmonary Alveolar ProteinosisApplication PCTUS2021052911Pending
- Separation Of Vancomycin And Its Degradation ProductsApplication PCTUS2019056382Pending
- Separation Of Vancomycin And Its Degradation ProductsApplication 62745772Pending
Related companies, and why
- SYNERGYS BIOTHERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- UNCO THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- Inspira Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- MARKER THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- ACHIEVE LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CELLIBRE INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .